
BioCardia Inc. (BCDA) Stock Forecast & Price Target
BioCardia Inc. (BCDA) Analyst Ratings
Bulls say
BioCardia Inc. is advancing its CardiAMP autologous mononuclear cell therapy platform, showing significant reductions in heart-related death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE) in high-risk patients, as demonstrated in their Phase 3 CardiAMPHF clinical trial. The company's therapies are particularly impactful for patients with elevated NTproBNP levels, indicating potential long-term benefits that may mitigate disease progression. With a focus on addressing unmet medical needs in cardiovascular and pulmonary diseases, BioCardia’s clinical advancements suggest a promising outlook driven by strong patient outcomes and a diversified therapeutic approach.
Bears say
BioCardia Inc. faces significant challenges as its CardiAMP autologous mononuclear cell therapy did not meet its primary three-tiered composite endpoint in the Phase 3 trial, limiting its prospects for clinical success. This unmet milestone raises concerns regarding the viability of its clinical programs, including the CardiALLO platform, which remains unforecasted in financial projections due to uncertainty. Additionally, the company's reliance on securing adequate funding and potential risks related to capital raises contribute to a negative outlook on its long-term financial stability and growth potential.
This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.
BioCardia Inc. (BCDA) Analyst Forecast & Price Prediction
Start investing in BioCardia Inc. (BCDA)
Order type
Buy in
Order amount
Est. shares
0 shares